Pharmacotherapy for bipolar disorder requires careful baseline and ongoing laboratory monitoring due to the distinct adverse effect profiles of mood stabilizers and second-generation antipsychotics. Match each of the following medications used in the management of bipolar disorder with its most appropriate baseline and ongoing laboratory monitoring requirement.
- LithiumBaseline and ongoing evaluation of renal function (BUN, creatinine) and thyroid function (TSH)
- ValproateBaseline hepatic panel, platelet counts, and pregnancy testing due to high teratogenic risk (neural tube defects)
- CarbamazepineBaseline complete blood count to evaluate for agranulocytosis and HLA-B*1502 screening in susceptible populations
- OlanzapineBaseline and regular assessment of fasting lipid panel, fasting blood glucose, and body mass index
Cevap
Lithium matches with renal and thyroid monitoring; Valproate matches with hepatic, platelet, and pregnancy screening; Carbamazepine matches with CBC and HLA-B*1502 screening; Olanzapine matches with metabolic panel monitoring.
Each mood stabilizer and antipsychotic used in bipolar disorder has specific baseline and ongoing laboratory monitoring requirements tied to its unique toxicity profile. Lithium impacts the thyroid and kidneys. Valproate can cause liver damage, decreased platelets, and severe birth defects. Carbamazepine can suppress the bone marrow and cause severe rashes in genetically susceptible individuals. Olanzapine is highly associated with metabolic syndrome.
Adım Adım Çözüm
Anahtar Kavram
Distinct adverse effect profiles of bipolar disorder medications dictate their specific laboratory monitoring requirements.